9 results about "GN - Glomerulonephritis" patented technology

The present disclosure provides methods of treating or reducing the symptoms of glomerulonephritis in a subject.

The utility model discloses an acute glomerulonephritis nursing auxiliary device which comprises a fixing frame, a sliding mechanism used for controlling the synchronous sliding direction is arranged in the fixing frame, the sliding mechanism comprises a rotating shaft rotationally connected to the interior of the fixing frame, a worm is fixedly connected to the rotating shaft, and the worm is fixedly connected to the fixing frame. And a fixing plate is fixedly connected to the interior of the fixing frame, a rotating roller is rotationally connected to the side, close to the worm, of the fixing plate, and a worm wheel is fixedly connected to the side, close to the worm, of the rotating roller. By arranging the sliding mechanism, the rotating handle can be rotated to drive the rotating shaft to rotate, the rotating shaft rotates to drive the worm on the rotating shaft to rotate synchronously, the worm rotates to drive the worm gear to rotate, the worm gear rotates to drive the threaded rod to rotate, and the threaded rod rotates to drive the nut on the threaded rod to slide. And finally, the nut can be synchronously pushed to slide through rotation of the rotating handle.

The application discloses a foot process identification method and device for electron microscope images of chronic kidney disease and terminal equipment, obtains the electron microscope pathological images of chronic kidney disease with labeled foot process position characteristics, and trains a preset deep network architecture through the electron microscope pathological images of chronic kidney disease to obtain a foot process identification model, so that when the electron microscope images of chronic kidney disease to be detected are obtained, the automatic identification of the foot process area corresponding to the electron microscope images to be detected can be realized through the obtained foot process identification model, and the automatic identification of the foot process area of the electron microscope images of chronic kidney disease is realized. The application accurately and quickly identifies the area corresponding to the foot process through the deep learning mode, improves the foot process identification efficiency of the electron microscope images of chronic kidney disease, is favorable to improving the pathological diagnosis and analysis efficiency of various types of glomerulonephritis for pathologists, and can reduce misdiagnosis and missed diagnosis caused by insufficient experience.

A composition comprising isolated Streptococcus pyogenes extracellular vesicles (EVs) suspended in a vehicle, for use in eliciting an adaptive immune response against group A streptococcus (GAS) in a subject. The EVs may comprise antigens MtsA, Spy_1228, PrsA1, PrsA2, SPy_0319 and / or GlnP. A composition comprising isolated S. pyogenes protein(s) MtsA, SPy_1228, PrsA1, PrsA2, GlnP, SPy_0319 and / or MalX. The compositions may be used for inducing protective immunity in a subject against a GAS infection, such as streptococcal pharyngitis, scarlet fever, impetigo, streptococcal meningitis, streptococcal sinusitis, necrotizing fasciitis, cellulitis, streptococcal toxic shock syndrome, rheumatic fever and post-streptococcal glomerulonephritis.

According to the lipid metabolism pathway marker of GK in obesity-related glomerulonephritis podocyte damage and the diagnosis application, the expression level of glycerol kinase in a tested sample is detected, and the expression level is compared with the corresponding expression level in a reference sample; diagnosis information for representing the abnormal state of the podocyte lipid metabolism pathway of the obesity-related glomerulonephritis is obtained based on the comparison result, and the expression level comprises the messenger ribonucleic acid expression level of glycerol kinase, the protein expression level or the combination of the messenger ribonucleic acid expression level and the protein expression level. A test sample comprises at least one of a kidney tissue sample, a serum sample, a plasma sample, a whole blood sample or a urine sample, and the related state of podocyte damage of obesity-related glomerulonephritis is subjected to molecular level characterization from the lipid metabolism pathway level; the method has the advantages of being clear in diagnosis directivity, suitable for multiple sample types, flexible in detection mode and capable of being used for disease layering and dynamic evaluation.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.

Methods for treating systemic lupus erythematosus using compounds or pharmaceutical compositions that modulate the activity of Bcl-2 family proteins are disclosed. In some methods, the patient to be treated is diagnosed with lupus nephritis. In some methods, the compound or pharmaceutical composition is administered to the patient in need thereof at a therapeutically effective dose sufficient to elicit one or more effects selected from: reduced excretion of protein in the urine of the patient, reduced serum anti-dsDNA autoantibody levels in the patient, reduced skin lesion severity in the patient, reduced lymphadenopathy severity in the patient, reduced glomerulonephritis severity in the patient, reduced vasculitis severity in the patient, reduced lymphocyte cell counts in a peripheral blood mononuclear cell (PMBC) panel taken from the patient, reduced lymphocyte cell counts in the spleen of the patient, and reduced lymphocyte infiltration of the kidneys of the patient.

The invention relates to the technical field of nephritis medicine, in particular to an AAGN disease blood or urine metabolism marker, a kit and application of the AAGN disease blood or urine metabolism marker. In the blood or urine metabolism markers, the blood metabolism marker comprises one or more of 2-hydroxyphenylacetic acid, galacturonic acid, D-mannose-6-phosphoric acid, 1-methyluric acid and L-rhamnose acid; the urine metabolism marker comprises one or more of phosphatidylserine PS (20: 020: 4), lysophosphatidylcholine LPC (0: 0 / 20: 2), phosphatidylcholine PC (20: 122: 6), phosphatidylcholine PC (O-18: 116: 0) and phosphatidylcholine PC (O-18: 120: 4). The metabolic marker combination and the kit are used for predicting treatment response of ANCA-related glomerulonephritis (AAGN) patients, and have good repeatability, stability and biological correlation.

The invention provides novel methods for treatment of patients with minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS) by administration of compositions comprising a therapeutic agent. According to the invention, the therapeutic agent for the treatment of MCD and / or FSGS may be an anti-CD19 antibody.